In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more

The group’s median market cap performance was positive

Plus: PTC reaps $1B from sale of Evrysdi royalties and updates from Sirius, BMS and Ultragenyx

Actio Biosciences founders argue for a refocusing of population-scale genomics efforts, with new goals and a bigger vision

Plus Biogen, Eisai seeking approval of lecanemab for Alzheimer’s, Transcenta IPO, ViiV, Innovent-Union and more